Millipore "worth every Euro," says Merck CEO Kley

Merck KGaA CEO Karl-Ludwig Kley says following the late February announcement of the company's acquisition of biotech supplier Millipore, he was asked more than once if the $6 billion price was too high. "I have a clear answer: No, Millipore is worth every euro," he says, as quoted in BusinessWeek. He adds the takeover "will transform" Merck's life science chemicals division. Article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.